Certain Type of Medicines Approved for Type 2 Diabetes and Obesity: Drug Safety Communication - Update on FDA’s Ongoing Evaluation of Reports of Suicidal Thoughts or Actions. Preliminary evaluation does not suggest a causal link.

The FDA has been evaluating reports of suicidal thoughts or actions in patients treated with a class of medicines called glucagon-like peptide-1 receptor agonists. FDA's preliminary evaluation has not found evidence that use of these medicines causes suicidal thoughts or actions.